We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
+295.98%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$4.77M
Cap. Flow
+$2.01M
Cap. Flow %
1.73%
Top 10 Hldgs %
98.03%
Holding
16
New
4
Increased
7
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
CABA icon
Cabaletta Bio
CABA
+$10.3M
2
MRUS
Merus
MRUS
+$4.25M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$2.64M
4
PVLA
Palvella Therapeutics
PVLA
+$2.12M
5
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$1.64M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$12M
2
JBIO
Jade Biosciences
JBIO
+$4.58M
3
IMUX icon
Immunic
IMUX
+$3.39M
4
CBAY
Cymabay Therapeutics
CBAY
+$2.56M
5
OTIC
Otonomy, Inc.
OTIC
+$682K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
1
Cabaletta Bio
CABA
$439M
$26.1M 22.61%
+2,825,976
New +$10.3M
ALPN
2
DELISTED
Alpine Immune Sciences Inc
ALPN
$23M 19.87%
3,126,173
+69,753
+2% +$446K
MRUS
3
DELISTED
Merus
MRUS
$13.2M 11.43%
854,591
+241,520
+39% +$4.25M
KNTE
4
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$12.2M 10.54%
1,998,417
+323,740
+19% +$2.64M
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$10.4M 8.97%
1,653,495
-672,338
-29% -$2.56M
BLU
6
DELISTED
BELLUS Health Inc.
BLU
$8.99M 7.78%
1,093,900
-1,288,227
-54% -$12M
PVLA
7
Palvella Therapeutics
PVLA
$1.98B
$5.85M 5.06%
70,357
+26,418
+60% +$2.12M
PRDS
8
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$5.08M 4.39%
3,003,102
+727,370
+32% +$922K
PASG icon
9
Passage Bio
PASG
$15.9M
$4.63M 4.01%
167,796
+30,175
+22% +$761K
THRX
10
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$3.91M 3.38%
784,158
+279,296
+55% +$1.64M
NGNE icon
11
Neurogene
NGNE
$696M
$1.17M 1.01%
+114,557
New +$1.18M
WHWK
12
Whitehawk Therapeutics
WHWK
$183M
$831K 0.72%
+64,739
New +$845K
PHVS icon
13
Pharvaris
PHVS
$2.39B
$285K 0.25%
+25,325
New +$133K
JBIO
14
Jade Biosciences
JBIO
$1.22B
– –
-7,898
Closed -$4.58M
IMUX icon
15
Immunic
IMUX
$182M
– –
-107,229
Closed -$3.39M
OTIC
16
DELISTED
Otonomy, Inc.
OTIC
– –
-2,312,880
Closed -$682K

Similar funds

SWM
SilverOak Wealth Management Edina, Minnesota $632M AUM 18.6% 1-Year Est. Return
RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return

Lynx1 Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Lynx1 Capital Management held 16 positions worth $116M, up 4.3% from $111M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Lynx1 Capital Management's Q4 2022 filing shows 4 new, 7 increased, 2 reduced and 3 closed positions. Its largest new stake was Cabaletta Bio: 2,825,976 shares worth $26.1M. The largest sale was BELLUS Health Inc., an estimated $12M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lynx1 Capital Management's largest Q4 2022 buy was Cabaletta Bio: 2,825,976 shares worth $26.1M.
  • Lynx1 Capital Management added most to Merus in Q4 2022, an estimated $4.25M increase.
  • Lynx1 Capital Management's biggest Q4 2022 reduction was BELLUS Health Inc., cutting an estimated $12M.
  • Lynx1 Capital Management fully exited Jade Biosciences in Q4 2022, selling an estimated $4.58M.
  • Lynx1 Capital Management's ten largest holdings make up 98% of its $116M portfolio in Q4 2022.
  • Lynx1 Capital Management opened 4 new positions and closed 3 in Q4 2022.
  • Lynx1 Capital Management's portfolio value rose 4.3% quarter-over-quarter to $116M.

Based on Lynx1 Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.